Bortezomib Liposome (PEGylated) (CAT#: LDLY-0724-LD66)

Description
Bortezomib (BTZ) is a proteasome inhibitor used to treat various malignancies, including lung cancer, prostate cancer, colorectal cancer, breast cancer, etc. This product is a pre-formulated liposome encapsulating Bortezomib. It is only for research purposes.
Lipid Composition
HSPC, Cholesterol, DSPE‑mPEG (2000)
Encapsulated Drug
Bortezomib
Buffer
PBS, pH 7.4
Storage
Store in dark at +4°C and do not freeze
Size
100-200 nm
Quantity
5mL (available in lyophilized powder)
Dosage
Download
DataSheet MSDS
Customer Reviews Related Sections

Click the button below to contact us or submit your feedback about this product.

Products
Services
Applications
Technical Support
For Research Use Only. Not For Clinical Use

Online Inquiry

Services
Liposome Development Service
Liposome Contract Manufacturing
Custom Lipid Synthesis Service
One-stop Liposome Research Solution
Lipid Nanoparticle (LNP) Development Service
Products
Liposomes
Phospholipids
Modified Lipids
Other Lipids
Liposomal Kits
Support
By Modality
By Indication
Formulation
Science
Background of Liposome
Resources
Platform
Contact Us
  • Tel:  (USA)
  •  (UK)
  •  (Germany)
  • Fax:
  • Email:
Social

Creative Biolabs is a world-leading liposome provider with extensive experience in liposome preparation, custom formulation development, and characterization.

© 2024 Creative Biolabs. All rights reserved.

Inquiry
Top